文献发表
沙砾生物研发团队在国际知名学术期刊发表多项研究成果，推动细胞治疗领域的科学进步
2026 年
Discover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical mapping study in a neuroendocrine cancer patient
Xinyu Gao, Zhenjiang Liu, Zhaoting Xu, Ke Liu, Yiming Zhang, Jing Yu, Xu Wang, Xinghua Cheng, Chao Ni, Pin Wang, Yarong Liu, Xinfang Hong, Jingwei Sun, Bing Zhao
In Vivo CAR-T Engineering with the Targeted Lentiviral Vector GT860 for Multiple Myeloma
Jingwei Sun, Jiahui Jin, Jingman Wang, Yiyang Tan, Zhao Xu, Xiaoling Yun, Pin Wang, Yarong Liu
First-in-human study of in vivo CAR-T therapy GT801 in adults with relapsed or refractory CD19-positive B-cell hematologic malignancies
Li Wang, Xianchao Ding, Zhiyang Xu, Zhenzhen Wang, Lihua Yan, Wei Xu, Pin Wang, Jing Yu, Liqing Ma, Hang Chen, Derun Shen, Jingwei Sun, and Yarong Liu
Safety and efficacy of GT719, an off-the-shelf CAR-NKT therapy, in adults with relapsed or refractory CD19-positive B-cell malignancies
Jing Yu, Dehui Zou, Hongsheng Zhou, Liqing Ma, Bowen Li, Hang Chen, Derun Shen, Sisi Feng, Jingwei Sun, Pin Wang, Yarong Liu
Targeted mRNA-LNP Delivery Enables In Vivo CAR-T Generation by GT801 with Potent B-Cell Depletion in Humans
Jingwei Sun, Xi Zhu, Jia hui Jin, Yiyang Tan, Zhao Xu, Jingman Wang, Hong Chen, Dalang Li, Jun Cui, Jing Yu, Pin Wang, Yarong Liu
GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study
Haifeng Qin, Yongsheng Wang, Yuyao Yi, Fang Gao, Dongling Zou, Yongsheng Li, Xiubao Ren, Dongmei Ji, Jian Zhang, Shasha Wang, Zhen Zeng, Jing Yu, Liqing Ma, Lili Lu, Wensheng Huang, Bowen Li, Derun Shen, Jun Cui, Yanbin Liu, Pin Wang, Yarong LiuASCO Annual Meeting 2026
An Off-the-Shelf Cord Blood HSC-Derived CD33/CD70 CAR-iNKT Cell Therapy (GT737) for Acute Myeloid Leukemia
Sisi Feng, Xiaona Xu, Jingman Wang, Jing Hao, Zhao Xu，Jingwei Sun, Pin Wang，Yarong Liu
Armored TIL GT201 Induces Potent Tumor-Specific TCR Expansion and Durable Antitumor Responses in Advanced Solid Tumor
Pin Wang, Rong Zhou, Yong Han, Zhengxiang Han, Weijia Fang, Kai Chen, Youguo Chen, Liqing Ma, Lili Lu, Derun Shen, Jiahui Jin, Yiyang Tan, Ke Liu, Zhenjiang Liu, Jingman Wang, Zhao Xu, Jingwei Sun, Jun Cui, Jing Yu, Yue He, Yarong Liu
Stem cell-derived allogeneic anti-CD19 CAR-iNKT cell therapy GT719 for relapsed/refractory B cell malignancies
Dehui Zou, Wei Liu, Yan Yu, Huimin Liu, Yi Wang, Sisi Feng, Xiaona Xu, He Zhang, Ershao Zhang, Jiang Li, Jingman Wang, Jing Hao, Ning Wang, Huipin Zheng, Yin Cheng, Jun Cui, Jingwei Sun, Yarong Liu
In vivo CAR-T T-LNP system (GT801) drives potent B cell depletion and clinical feasibility in hematologic and autoimmune conditions
Jingwei Sun, Xi Zhu, Jiahui Jin, Yiyang Tan, Liang Lin, Zhao Xu, Jingman Wang, Dalang Li, Hong Chen, Jiaming Ren, Jun Cui, Jing Yu, Pin Wang, Yarong Liu
Evaluation of autologous tumor-infiltrating lymphocytes (GT201) plus toripalimab in recurrent or metastatic head and neck cancer
Yue He, Rong Zhou, Yong Han, Pin Wang, Jing Yu, Liqing Ma, Suqiong Lu, Lili Lu, Derun Shen, Yarong Liu
2025 年
High-fidelity AaCas12bMax enables the development of an engineered T cell therapy with enhanced safety and functional fitness
Jingwei Sun, Ke Liu, Yao Sheng, Hongwei Zhang, Jingman Wang, Yueqiang Wang, Rui Tian, Xi Zhu, Shin-Shay Tian, Pin Wang, Xiaoping Zhao, Yarong Liu
Engineering DNA Origami Captors for TGF-β1 Sequestration to Enhance Tumor Immune Modulation and Therapy
Xiao Chen, Dunfang Liu, Jiahui Jin, Han Yao, Yao Sheng, Yarong Liu, Jingwei Sun, Yang Yang
A Bispecific Engager-Secreting TIL Therapy Designed to Penetrate Stromal Barriers and Boost Tumor Killing in Solid Tumors
Jingwei Sun, Yiyang Tan, Jiahui Jin, Jingman Wang, Fengbiao Guo, Zhao Xu, Pin Wang, Yarong Liu
GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study
Haifeng Qin, Yongsheng Wang, Yuyao Yi, Fang Gao, Dongling Zou, Yongsheng Li, Xiubao Ren, Dongmei Ji, Jian Zhang, Shasha Wang, Zhen Zeng, Liqing Ma, Yishan Liu, Lili Lu, Xue Wei, Derun Shen, Pin Wang, Yarong Liu, Jing Yu
Enhancing Production and Functional Potential of Tumor-Infiltrating Lymphocytes via Lipid Nanoparticle-Mediated CRISPR/Cas9 Gene Editing
Jingwei Sun, Yao Sheng, Fei Li, Ke Liu, Xi Zhu, Hong Chen, Pin Wang, Yarong Liu
Next-generation neoantigen vaccines powered by AI-assisted discovery and APC-targeted delivery platforms
Jingwei Sun, Zhenjiang Liu, Ke Liu,Xi Zhu, Chenxi Hou, Hong Chen, Xu Wang, Jiahui Jin, Zhao Xu, Pin Wang, Yarong Liu
GT316: a next-generation TIL therapy identified through genome-wide CRISPR screening with promising efficacy in advanced solid tumors
Jingwei Sun, Yao Sheng, Jingman Wang, Jiahui Jin, Zhao Xu, JIng Yu, Jing Guo, Zhongping Cheng, Pin Wang, Yarong Liu
Engineering a next-generation dual-knockout TIL product with AaCas12b nuclease editing
Jingwei Sun, Yao Sheng, Hongwei Zhang,Xi Zhu, Jingman Wang, Ke Liu, Shin-Shay Tian, Pin Wang, Xiaoping Zhao, Yarong Liu
APC-Targeted LNP Enables Systemic Delivery of Neoantigen mRNA Vaccines and Enhanced Antigen-Specific T Cell Responses
Jingwei Sun, Xi Zhu, Zhao Xu, Ke Liu, Chenxi Hou, Hong Chen, Jiaming Ren, Zhenjiang Liu, Pin Wang, Yarong Liu
Precision In Vivo CAR-T generation via CLAMP-enabled mRNA delivery: Toward scalable and translatable cell therapy
Jingwei Sun, Xi Zhu, Zhao Xu, Jiahui Jin, Jingman Wang, Yiyang Tan, Dalang Li, Hong Chen, Jiaming Ren, Pin Wang, Yarong Liu
Assessing the safety and efficacy of GT201: A first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors
Pin Wang, Jing Yu, Yue He, Zhengxiang Han, Weijia Fang, Kai Chen, Youguo Chen, Rong Zhou, Yong Han, Liqing Ma, Yishan Liu, Lili Lu, Derun Shen, Yarong Liu
A Translatable In Vivo CAR-T Platform Enabled by CLAMP Technology for Targeted mRNA Delivery to T Cells
Jingwei Sun, Xi Zhu, Zhao Xu, Jiahui Jin, Dalang Li, Hong Chen, Jiaming Ren, Pin Wang, Yarong Liu
Trial in Progress: First in Human Study of GT601, a Next-Generation Neoantigen Cancer Vaccine for Hepatocellular Carcinoma
Pin Wang, Liqing Ma, Meng Zhao, Zhenjiang Liu, Yanbin Liu, Jun Cui, Xi Zhu, Jingwei Sun, Jing Yu, Yarong Liu
In Vivo CAR-T Therapy Powered by Novel CLAMP Technology for T cell-Targeted mRNA Delivery
Jingwei Sun, Xi Zhu, Zhongzheng Cao, Zhao Xu, Dalang Li, Hong Chen, Jiaming Ren, Pin Wang, Yarong Liu
Evaluating the safety and efficacy of CRISPR/AaCas12bMax-modified tumor infiltrating lymphocytes (GT300) as monotherapy in advanced solid tumors
Pin Wang, Haifeng Qin, Zhengxiang Han, Jing Guo, Jing Yu, Liqing Ma, Lili Lu, Hanyi Zhang, Yishan Liu, Jia Deng, Yarong Liu
2024 年
T cell receptor repertoire characteristics and therapeutic potential of tumor-infiltrating lymphocytes (TILs) derived from metastatic lymph node in cervical cancer
Xuan Zhao, Zhenjiang Liu, Haifeng Qin, Yarong Liu, Yi Zhang
The Discovery and Development of GT316 as a CRISPR/Cas9-Dual KO Anti-Exhaustion TIL Product for Advanced Solid Tumors
Yarong Liu,Jingwei Sun,Yao Sheng,Jingman Wang,Jiahui Jin,Fei Li,Lingyun Chen,Di Zhou,Yongchao Tan,Quanwei Wang,Zhao Xu,Haibao Li,Pin Wang,Jun Cui
A first-in-human study of CRISPR/Cas9-engineered tumor infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors
Jing Guo, Wei Huang, Binghui Zhao, Jing Yu, Jun Cui, Jingwei Sun, Liqing Ma, Yishan Liu, Derun Shen, Lin Shen, Pin Wang, Yarong Liu, and Zhongping Cheng
Phase 1 Study of GT101 as an Autologous Tumor Infiltrating Lymphocyte Therapy in Advanced Solid Tumors
Haifeng Qin, Yongsheng Wang, Yuyao Yi, Fang Gao, Dongling Zou, Yongsheng Li, Xiubao Ren, Dongmei Ji, Jian Zhang, Shasha Wang, Zhen Zeng, Jing Yu, Liqing Ma, Yishan Liu, Lili Lu, Derun Shen, Xue Zhai, Pin Wang, and Yarong Liu
Generation of tumor-reactive T cells by co-culture of tumor-infiltrating lymphocytes (TILs) and patient-derived organoids (PDOs)
Zhenjiang Liu,Jingwei Sun,Xinyu Gao,Xu Wang,Ke Liu,Chao Ni,Pin Wang,Bing Zhao,Yarong Liu
Trial in Progress: First-in-Human Study of Next-Generation Dual-KO TIL Therapy GT300 in Patients with Advanced Solid Tumors
Yarong Liu,Yu Jing,Lili Lu,Liqing Ma,Jingwei Sun,Pin Wang
Development of a next-generation dual-KO TIL product GT300 with AaCas12bMax nuclease
Jingwei Sun,Yao Sheng,Hongwei Zhang,Xi Zhu,Jingman Wang,Ke Liu,Shin-Shay Tian,Pin Wang,Xiaoping Zhao,Yarong Liu
Exploring the Safety and Efficacy of GT201 as a First-in-Class Autologous Tumor-Infiltrating Lymphocyte Monotherapy in Advanced Solid Tumors
Zhengxiang Han, Weijia Fang, Kai Chen, Youguo Chen, Hongmei Wang, Juanjuan Tang, Jing Yu, Liqing Ma, Yishan Liu, Lili Lu, Derun Shen, Xue Zhai, Pin Wang, and Yarong Liu
Unleashing the Potential of NK Cell Therapy by Genetic Disruption of Key Immunoregulators Identified via ImmuT Finder® Platform
Grit Bio
A CRISPR/Cas9 screening platform ImmuT Finder® enables in vivo T cell functional screening and identification of potent immunoregulatory targets for next-generation T cell therapy
Jingwei Sun,Jiahui Jin,Jingman Wang,Yao Sheng,Fei Li,Lingyun Chen,Yongchao Tan,Zhao Xu,Yanbin Liu,Ke Liu,Yarong Liu
A genetically modified tumor-infiltrating lymphocytes product (GT216) enhanced anti-tumor efficacy against solid tumor by fine-tuning multiple negative immune regulators
Jingwei Sun,Yiyang Tan,Jiahui Jin,Jingman Wang, Lingyun Chen, Fengbiao Guo,Yongchao Tan,Zhao Xu,Yarong Liu
2023 年
Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy
Hao Feng, Ling Qiu, Zixiao Shi, Yao Sheng, Peipei Zhao, Di Zhou, Fei Li, Hailin Yu, Yanan You, Hui Wang, Ming Li, Shurong Zhu, Yan Du, Jun Cui, Jingwei Sun, Yarong Liu, Hua Jiang, Xin Wu
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer
Yanbin Liu, Zhenjiang Liu, Yixiao Yang, Jun Cui, Jingwei Sun, Yarong Liu
The discovery and development of a CRISPR/Cas9-engineered tumor-infiltrating lymphocytes product (GT316) as a next-generation TIL therapy
Yarong Liu, Jingwei Sun,Yao Sheng,Jingman Wang,Jiahui Jin,Fei L,Lingyun Chen,Di Zhou,Yongchao Tan,Quanwei Wang,Zhao Xu,Haibao Li,Pin Wang,Jun Cui
A Functionally Enhanced Tumor-Infiltrating Lymphocytes Product (GT201) Exhibits Improved Persistence and Anti-Tumor Efficacy With Low IL-2 Dependency
Jingwei Sun, Jiahui Jin, Quanwei Wang, Yiyang Tan, Jingman Wang, Yongchao Tan, Zhao Xu, Lingyun Chen, Pin Wang, Yarong Liu
Distinct predictive value of CD137 as a tumor reactive marker among different cancer types and TIL expansion stage
Zhenjiang Liu,Jingwei Sun,Zixiao Shi,Peipei Zhao,Quanwei Wang,Xu Wang,Pin Wang,Yarong Liu
Expansion of Tumor-Infiltrating Lymphocytes (TILs) with Substantial Stemness Properties from Vulvar Cancer
Tingting Yao, Zixiao Shi, Jingwei Sun, Yuhan Wang, Haijian Zhou, Yanru Chen, Di Zhou, Zhongqiu Lin, Yarong Liu
2022 年
A genetically modified tumor-infiltrating lymphocytes product (GT202) exhibits enhanced persistence and anti-tumor efficacy against solid tumor in vivo
Jingwei Sun,Jiahui Jin,Yongchao Tan,Lingyun Chen,Quanwei Wang,Yarong Liu
Modulation of intracellular kinase signaling to improve TIL manufacturing for adoptive cell therapy
Zixiao Shi,Sheng Yao,Peipei Zhao,Fei Li,Di Zhou,Jun Cui,Jingwei Sun,Yarong Liu
2021 年
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
Shuhang Wang, Jingwei Sun, Kun Chen, Peiwen Ma, Qi Lei, Shujun Xing, Zhongzheng Cao, Shujun Sun, Zicheng Yu, Yarong Liu, Ning Li
The Landscape of Cell and Gene Therapies for Solid Tumors
Shuhang Wang, Fa Sun, Huiyao Huang, Kun Chen, Qi-Jing Li, Lu Zhang, Enxiu Wang, Chen Wang, Hai Zhang, Andy Qingan Yuan, Bin Chen, Tao Deng, Yarong Liu, Jingwei Sun, Dongfang Liu, Yue Yu, Yuan Fang, Ning Jiang, Dawei Wu, Hong Fang, Ying Bai, Shujun Xing, Yufen Ni, Qi Fan, Anqi Yu, Chao Sun, Yu Tang, Ning Li, Binghe Xu, Jie He
《细胞治疗》专著
主编：王明伟；副主编：王方敏、贾国栋、吴健、郝好杰；编委：丁佳、王华、王钰、王方敏、王立群、王明伟、史春梦、任艺虹、刘雅容等
2020 年
The toxicity of cell therapy: Mechanism, manifestations, and challenges
Yongjia Jin, Yan Dong, Jin Zhang, Jingwei Sun, Yarong Liu, Yong Chen